<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39277739</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>17</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2055-0936</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>15</Day></PubDate></JournalIssue><Title>Tropical diseases, travel medicine and vaccines</Title><ISOAbbreviation>Trop Dis Travel Med Vaccines</ISOAbbreviation></Journal><ArticleTitle>A post-marketing study to evaluate the safety and immunogenicity of a quadrivalent influenza split-virion vaccine in elderly people aged 60 years and older.</ArticleTitle><Pagination><StartPage>18</StartPage><MedlinePgn>18</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">18</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s40794-024-00228-x</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Influenza remains a global public health concern. Understanding the vaccination-induced response in an aging population, which is susceptible and at high risk, is essential for disease prevention and control. Here, we report findings on the safety and immunogenicity of a quadrivalent influenza split-virion vaccine (15 µg/subtype/0.5 ml/dose) (hereinafter referred to as the "quadrivalent influenza vaccine") in a population aged ≥ 60 years.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This open-label, pragmatic post-marketing trial enrolled 1399 older adults to receive one dose of an approved commercially available quadrivalent influenza vaccine manufactured by Hualan Biological Bacterin Inc. (hereinafter referred to as "Hualan Bio"). Participants with contraindications for the vaccine were excluded, while poor health condition was acceptable. All vaccinated subjects experienced adverse events collection within 30 days and serious adverse events within 180 days post-vaccination. 25% subjects, selected randomly, underwent venous blood sampling pre-vaccination and 30 days after post-vaccination, for detecting antibody titers against each subtype of influenza virus by hemagglutination inhibition assay. The incidences of adverse events and antibody titers against each subtype of influenza virus were statistically analyzed using SAS 9.4.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">No grade 3 adverse reactions occurred within 30 days post-vaccination. The incidences of overall adverse reactions, local adverse reactions and systemic adverse reactions were 3.79%, 2.86% and 1.00%, respectively. No serious adverse reactions occurred within 180 days post-vaccination. There were 350 subjects who completed venous blood sampling pre-vaccination, among whom 348 subjects completed venous blood sampling at 30 days post-vaccination for immunogenicity assessment. With respect to hemagglutination inhibition antibodies against influenza viruses H1N1, H3N2, BV and BY subtypes, at 30 days post-vaccination, the seroconversion rates were 87.64%, 75.57%, 73.28% and 78.74%, respectively; the seropositive rates were 93.97%, 98.56%, 79.31% and 95.40%, respectively; and the geometric mean increase (GMI) in post-immunization/pre-immunization antibodies was 24.80, 7.26, 10.39 and 7.39, respectively.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">One 15 µg/subtype dose of the vaccine had a good safety profile and elicited favorable immunogenicity among subjects aged ≥ 60 years. The results of this study indicate that Hualan Bio quadrivalent influenza vaccine strike balance between safety and immunogenicity, supporting unnecessity to increase dosage or inoculation frequency for further enhancing immunogenicity.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">Registered on ClinicalTrials.gov.</AbstractText><AbstractText Label="REGISTRATION NUMBER" NlmCategory="BACKGROUND">NCT06334510. Registered on 28/03/2024 (retrospectively registered).</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kou</LastName><ForeName>Zengqiang</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Shandong Center for Disease Control and Prevention, Jinan, 250014, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xiaoyu</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>National Institutes for Food and Drug Control, Beijing, 102600, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Ti</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Shandong Center for Disease Control and Prevention, Jinan, 250014, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fan</LastName><ForeName>Bei</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Hualan Biological Engineering Inc, Xinxiang, 453003, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>An</LastName><ForeName>Wenqi</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Hualan Biological Engineering Inc, Xinxiang, 453003, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>An</LastName><ForeName>Wenjue</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Hualan Biological Bacterin Inc, No. 1-1, Hualan Avenue, Xinxiang City, Henan Province, 453003, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dang</LastName><ForeName>Mingan</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Henan Center for Drug Evaluation and Inspection, Zhengzhou, 450008, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Ke</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Hualan Biological Bacterin Inc, No. 1-1, Hualan Avenue, Xinxiang City, Henan Province, 453003, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Jingning</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Hualan Biological Bacterin Inc, No. 1-1, Hualan Avenue, Xinxiang City, Henan Province, 453003, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Nan</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Hualan Biological Bacterin Inc, No. 1-1, Hualan Avenue, Xinxiang City, Henan Province, 453003, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pan</LastName><ForeName>Ruowen</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Hualan Biological Bacterin Inc, No. 1-1, Hualan Avenue, Xinxiang City, Henan Province, 453003, China. hlym2005@outlook.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Trop Dis Travel Med Vaccines</MedlineTA><NlmUniqueID>101674442</NlmUniqueID><ISSNLinking>2055-0936</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Elderly people</Keyword><Keyword MajorTopicYN="N">Immunogenicity</Keyword><Keyword MajorTopicYN="N">Quadrivalent influenza split-virion vaccine</Keyword><Keyword MajorTopicYN="N">Safety</Keyword><Keyword MajorTopicYN="N">Vaccination</Keyword></KeywordList><CoiStatement>R.P., Wenjue A., K.Z., J.T. and N.Z are employed in Hualan Biological Bacterin Inc. that funded this research. B.F. and Wenqi A. are employed in Hualan Biological Engineering Inc. that is the parent company of Hualan Biological Bacterin Inc. Z.K. is employed in Shandong Center for Disease Control and Prevention that was responsible for implement of this research. Other authors report there are no competing interests to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>6</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>15</Day><Hour>14</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>15</Day><Hour>14</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>14</Day><Hour>23</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39277739</ArticleId><ArticleId IdType="pmc">PMC11402193</ArticleId><ArticleId IdType="doi">10.1186/s40794-024-00228-x</ArticleId><ArticleId IdType="pii">10.1186/s40794-024-00228-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kim YH, Hong KJ, Kim H, Nam JH. Influenza vaccines: past, present, and future. Rev Med Virol. 2021. 10.1002/rmv.2243. 10.1002/rmv.2243</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.2243</ArticleId><ArticleId IdType="pmc">PMC8209895</ArticleId><ArticleId IdType="pubmed">33949021</ArticleId></ArticleIdList></Reference><Reference><Citation>Paules C, Subbarao K. Influenza Lancet. 2017. 10.1016/s0140-6736(17)30129-0. 10.1016/s0140-6736(17)30129-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(17)30129-0</ArticleId><ArticleId IdType="pubmed">28302313</ArticleId></ArticleIdList></Reference><Reference><Citation>https://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal). Accessed.</Citation></Reference><Reference><Citation>Somes MP, Turner RM, Dwyer LJ, Newall AT. Estimating the annual attack rate of seasonal influenza among unvaccinated individuals: a systematic review and meta-analysis. Vaccine. 2018. 10.1016/j.vaccine.2018.04.063. 10.1016/j.vaccine.2018.04.063</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2018.04.063</ArticleId><ArticleId IdType="pubmed">29716771</ArticleId></ArticleIdList></Reference><Reference><Citation>Quach HQ, Kennedy RB. Enhancing immunogenicity of Influenza Vaccine in the Elderly through Intradermal Vaccination: A literature analysis. Viruses; 2022. 10.3390/v14112438.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9698533</ArticleId><ArticleId IdType="pubmed">36366536</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu H, Huang J, Huai Y, Guan X, Klena J, Liu S, et al. The substantial hospitalization burden of influenza in central China: surveillance for severe, acute respiratory infection, and influenza viruses, 2010–2012. Influenza and Other Respiratory Viruses; 2014. 10.1111/irv.12205.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4177798</ArticleId><ArticleId IdType="pubmed">24209711</ArticleId></ArticleIdList></Reference><Reference><Citation>Iuliano AD, Roguski KM, Chang HH, Muscatello DJ, Palekar R, Tempia S, et al. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. Lancet. 2018. 10.1016/s0140-6736(17)33293-2. 10.1016/s0140-6736(17)33293-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(17)33293-2</ArticleId><ArticleId IdType="pmc">PMC5935243</ArticleId><ArticleId IdType="pubmed">29248255</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L, Liu Y, Wu P, Peng Z, Wang X, Chen T, et al. Influenza-associated excess respiratory mortality in China, 2010–15: a population-based study. Lancet Public Health. 2019. 10.1016/s2468-2667(19)30163-x. 10.1016/s2468-2667(19)30163-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s2468-2667(19)30163-x</ArticleId><ArticleId IdType="pmc">PMC8736690</ArticleId><ArticleId IdType="pubmed">31493844</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, Fu C, Li K, Lu J, Chen Y, Lu E, et al. Influenza associated mortality in Southern China, 2010–2012. Vaccine. 2014. 10.1016/j.vaccine.2013.12.013. 10.1016/j.vaccine.2013.12.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2013.12.013</ArticleId><ArticleId IdType="pubmed">24370709</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng L, Shay DK, Jiang Y, Zhou H, Chen X, Zheng Y, et al. Influenza-associated mortality in temperate and subtropical Chinese cities, 2003–2008. Bull World Health Organ. 2012. 10.2471/blt.11.096958. 10.2471/blt.11.096958</Citation><ArticleIdList><ArticleId IdType="doi">10.2471/blt.11.096958</ArticleId><ArticleId IdType="pmc">PMC3324869</ArticleId><ArticleId IdType="pubmed">22511824</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu P, Goldstein E, Ho LM, Yang L, Nishiura H, Wu JT, et al. Excess mortality Associated with Influenza A and B Virus in Hong Kong, 1998–2009. J Infect Dis. 2012. 10.1093/infdis/jis628. 10.1093/infdis/jis628</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jis628</ArticleId><ArticleId IdType="pmc">PMC3502382</ArticleId><ArticleId IdType="pubmed">23045622</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang L, Ma S, Chen PY, He JF, Chan KP, Chow A, et al. Influenza associated mortality in the subtropics and tropics: results from three Asian cities. Vaccine. 2011. 10.1016/j.vaccine.2011.09.071. 10.1016/j.vaccine.2011.09.071</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.09.071</ArticleId><ArticleId IdType="pmc">PMC7115499</ArticleId><ArticleId IdType="pubmed">21959328</ArticleId></ArticleIdList></Reference><Reference><Citation>Demicheli V, Jefferson T, Di Pietrantonj C, Ferroni E, Thorning S, Thomas RE, et al. Vaccines for preventing influenza in the elderly. Cochrane Database Syst Reviews. 2018. 10.1002/14651858.CD004876.pub4.10.1002/14651858.CD004876.pub4</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD004876.pub4</ArticleId><ArticleId IdType="pmc">PMC6491101</ArticleId><ArticleId IdType="pubmed">29388197</ArticleId></ArticleIdList></Reference><Reference><Citation>Beyer WEP, McElhaney J, Smith DJ, Monto AS, Nguyen-Van-Tam JS, Osterhaus ADME. Cochrane re-arranged: support for policies to vaccinate elderly people against influenza. Vaccine. 2013. 10.1016/j.vaccine.2013.09.063. 10.1016/j.vaccine.2013.09.063</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2013.09.063</ArticleId><ArticleId IdType="pubmed">24095882</ArticleId></ArticleIdList></Reference><Reference><Citation>Che X, Liu Y, Gu W, Wang F, Wang J, Jiang W, et al. Analysis on the intention and influencing factors of free influenza vaccination among the elderly people aged 70 and above in Hangzhou in 2022. Front Public Health. 2023. 10.3389/fpubh.2022.1052500. 10.3389/fpubh.2022.1052500</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2022.1052500</ArticleId><ArticleId IdType="pmc">PMC9853049</ArticleId><ArticleId IdType="pubmed">36684888</ArticleId></ArticleIdList></Reference><Reference><Citation>EMEA, NOTE FOR GUIDANCE ON HARMONISATION OF REQUIREMENTS FOR INFLUENZA, VACCINES. 1997. https://www.ema.europa.eu/en/harmonisation-requirements-influenza-vaccines. Accessed 04 Mar 2024.</Citation></Reference><Reference><Citation>FDA-CBER. Clinical Data Needed to Support the Licensure of Seasonal Inactivated Influenza Vaccines. 2007. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-data-needed-support-licensure-seasonal-inactivated-influenza-vaccines. Accessed 04 Mar 2024.</Citation></Reference><Reference><Citation>ECDC, Systematic review of the efficacy, effectiveness and safety of newer and enhanced seasonal influenza vaccines for the prevention of laboratory-confirmed influenza in individuals aged 18 years and over. 2020. 10.2900/751620.</Citation></Reference><Reference><Citation>Stassijns J, Bollaerts K, Baay M, Verstraeten T. A systematic review and meta-analysis on the safety of newly adjuvanted vaccines among children. Vaccine. 2016. 10.1016/j.vaccine.2015.12.024. 10.1016/j.vaccine.2015.12.024</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2015.12.024</ArticleId><ArticleId IdType="pubmed">26740250</ArticleId></ArticleIdList></Reference><Reference><Citation>Grohskopf LA, Blanton LH, Ferdinands JM, Chung JR, Broder KR, Talbot HK, et al. Prevention and Control of Seasonal Influenza with vaccines: recommendations of the Advisory Committee on Immunization practices — United States, 2022–23 influenza season. MMWR Recomm Rep; 2022. 10.15585/mmwr.rr7101a1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9429824</ArticleId><ArticleId IdType="pubmed">36006864</ArticleId></ArticleIdList></Reference><Reference><Citation>NMPA. Guidelines for the classification of adverse events in clinical trials of preventive vaccines. 2019. https://www.nmpa.gov.cn/xxgk/ggtg/ypggtg/ypqtggtg/20191231111901460.html. Accessed 04 Mar 2024.</Citation></Reference><Reference><Citation>NMPA. Technical Guidelines for Clinical Research of Seasonal Influenza Virus Vaccine (Exposure Draft). 2021. https://www.cde.org.cn/main/news/viewInfoCommon/237d5f7de6bcfcd08037dcce873794f3. Accessed 04 Mar 2024.</Citation></Reference><Reference><Citation>Huang X, Fan T, Li L, Nian X, Zhang J, Gao X, et al. Safety and immunogenicity of a quadrivalent, inactivated, split-virion influenza vaccine (IIV4-W) in healthy people aged 3–60 years: a phase III randomized clinical noninferiority trial. Human Vaccines &amp; Immunotherapeutics; 2022. 10.1080/21645515.2022.2079924.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9621009</ArticleId><ArticleId IdType="pubmed">35714276</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X, Park J, Xia S, Liang B, Yang S, Wang Y, et al. Immunological non-inferiority and safety of a quadrivalent inactivated influenza vaccine versus two trivalent inactivated influenza vaccines in China: results from two studies. Human Vaccines &amp; Immunotherapeutics; 2022. 10.1080/21645515.2022.2132798.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9746500</ArticleId><ArticleId IdType="pubmed">36328438</ArticleId></ArticleIdList></Reference><Reference><Citation>National Bureau of Statistics. State Statistics Bureau Bulletin of the seventh national population Census (No.5). 2021. https://www.stats.gov.cn/sj/tjgb/rkpcgb/qgrkpcgb/202302/t20230206_1902005.html. Accessed 04 Mar 2024.</Citation></Reference><Reference><Citation>Kackos CM, DeBeauchamp J, Davitt CJH, Lonzaric J, Sealy RE, Hurwitz JL, et al. Seasonal quadrivalent mRNA vaccine prevents and mitigates influenza infection. npj Vaccines. 2023. 10.1038/s41541-023-00752-5. 10.1038/s41541-023-00752-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-023-00752-5</ArticleId><ArticleId IdType="pmc">PMC10570305</ArticleId><ArticleId IdType="pubmed">37828126</ArticleId></ArticleIdList></Reference><Reference><Citation>Mooring EQ, Bansal S. Increasing herd immunity with influenza revaccination. Epidemiol Infect. 2015. 10.1017/s0950268815002253. 10.1017/s0950268815002253</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/s0950268815002253</ArticleId><ArticleId IdType="pubmed">26482721</ArticleId></ArticleIdList></Reference><Reference><Citation>Hitchings MDT, Lipsitch M, Wang R, Bellan SE. Competing effects of Indirect Protection and Clustering on the power of cluster-randomized controlled vaccine trials. Am J Epidemiol. 2018. 10.1093/aje/kwy047. 10.1093/aje/kwy047</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kwy047</ArticleId><ArticleId IdType="pmc">PMC6070038</ArticleId><ArticleId IdType="pubmed">29522080</ArticleId></ArticleIdList></Reference><Reference><Citation>Law KB, Peariasamy KM, Mohd Ibrahim H, Abdullah NH. Modelling infectious diseases with herd immunity in a randomly mixed population. Sci Rep. 2021. 10.1038/s41598-021-00013-2. 10.1038/s41598-021-00013-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-00013-2</ArticleId><ArticleId IdType="pmc">PMC8523531</ArticleId><ArticleId IdType="pubmed">34663839</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>